ADMD (ADMD) Stock Price, News & Analysis

Company Overview

Vivos, Inc. is a radiation oncology medical device company. It is engaged in the development of its yttrium-90 based brachytherapy device, RadioGel, for the treatment of non-resectable tumors. The firm's product, RadioGel, is an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals. The company was founded by James C. Katzaroff on December 23, 1994 and is headquartered in Richland, WA.

Key Stats

• Today's Range: $0.04 to $0.05
• 50-Day Range: N/A
• 52-Week Range: $0.02 to $0.18
• Volume: 372,355 shs
• Average Volume: 224,348 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ADMD Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of ADMD own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ADMD investors own include Cara Therapeutics (CARA), 22nd Century Group (XXII), Flexion Therapeutics (FLXN), ADTRAN (ADTN), Canopy Growth (CGC), United Cannabis (CNAB) and Aadi Bioscience (AADI).

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Medical Specialties
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:ADMD
• CIK: 1449349
• Web: www.radiogel.com
• Phone: (509) 736-4000
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A